Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
Jarushka Naidoo, Catherine J. Murphy, Michael B. Atkins, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 3, pp. e006398-e006398
Open Access | Times Cited: 67

Showing 26-50 of 67 citing articles:

Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression
Jeffrey A. Sparks
Rheumatic Disease Clinics of North America (2024) Vol. 50, Iss. 2, pp. 147-159
Closed Access | Times Cited: 3
Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta‐analysis
Shoutao Dang, Xinyu Li, Heshu Liu, et al.
Cancer Medicine (2024) Vol. 13, Iss. 7
Open Access | Times Cited: 3
Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers
Pierre-Louis Cariou, Cédric Pobel, Jean‐Marie Michot, et al.
European Journal of Cancer (2024) Vol. 204, pp. 114065-114065
Closed Access | Times Cited: 3
Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors
Simone Rossi, Antonio Farina, Antonio Malvaso, et al.
Neurology Neuroimmunology & Neuroinflammation (2024) Vol. 11, Iss. 6
Open Access | Times Cited: 3
Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study
Claudia Ertl, T. Ruf, Linda Hammann, et al.
European Journal of Cancer (2024) Vol. 212, pp. 115049-115049
Open Access | Times Cited: 3
Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges
Claire E. T. O'Leary, Nicole Pierce, Sandip Pravin Patel, et al.
Journal of Thoracic Oncology (2023) Vol. 19, Iss. 3, pp. 395-408
Open Access | Times Cited: 8
Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Namrata Singh, Anupama Shahane, Jeffrey A. Sparks, et al.
Rheumatic Disease Clinics of North America (2024) Vol. 50, Iss. 2, pp. 269-279
Closed Access | Times Cited: 2
Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors
Letícia Alserawan, Maria Mulet, Geòrgia Anguera, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1759-1759
Open Access | Times Cited: 2
Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy
Muhammad Ali, Marc Eid, Renée Maria Saliby, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 2
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations
Annette M. Lim, Christophe Le Tourneau, Chris Hurt, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 7, pp. e308-e317
Closed Access | Times Cited: 2
Toxicity, disease management and outcome of treatment with immune checkpoint inhibitors by sex in patients with cancer and preexisting autoimmune disease
Michael Liu, Lisa Christ, Anke Richters, et al.
Oncology Letters (2023) Vol. 26, Iss. 3
Open Access | Times Cited: 5
A case of rapidly progressive insulin-dependent diabetes mellitus without islet autoantibodies developed over two years after the first dose of nivolumab
Kota Nishihama, Yuko Okano, Chisa Inoue, et al.
Diabetology International (2024) Vol. 15, Iss. 3, pp. 583-588
Closed Access | Times Cited: 1
Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden
Osama Hamida, Frans Karlsson, Andreas Lundqvist, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden
Osama Hamida, Frans Karlsson, Andreas Lundqvist, et al.
OncoImmunology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 1
Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy
Gerald J. Sun, Gustavo Arango-Argoty, Gary J. Doherty, et al.
iScience (2024) Vol. 27, Iss. 9, pp. 110634-110634
Open Access | Times Cited: 1
Multiple gastrointestinal immune related adverse events from immune checkpoint inhibitor therapy
Trevor Barlowe, Shruti Saxena, Rumey C. Ishizawar, et al.
Clinical and Translational Gastroenterology (2024) Vol. 15, Iss. 11, pp. e00768-e00768
Open Access | Times Cited: 1
Phenotypic insights into genetic risk factors for immune-related adverse events in cancer immunotherapy
Haochuan Ma, Dili Song, Haibo Zhang, et al.
Cancer Immunology Immunotherapy (2024) Vol. 74, Iss. 1
Open Access | Times Cited: 1
Trial Design for Cancer Immunotherapy: A Methodological Toolkit
Everardo D. Saad, Elisabeth Coart, Vaiva Deltuvaite‐Thomas, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4669-4669
Open Access | Times Cited: 4
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)
Paolo A. Ascierto, Sanjiv S. Agarwala, Allison Betof Warner, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 2
The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab
Katherine E. Smith, Stephanie L. Pritzl, Wei Yu, et al.
JTO Clinical and Research Reports (2023) Vol. 4, Iss. 12, pp. 100611-100611
Open Access | Times Cited: 2
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
Alexandra Ladouceur, Thomas Barnetche, Gaël Mouterde, et al.
RMD Open (2023) Vol. 9, Iss. 4, pp. e003795-e003795
Open Access | Times Cited: 2
Gestion des toxicités des immunothérapies du cancer : challenges et « rechallenges » pour les (jeunes) internistes
R. Guitton, Olivier Lambotte, Laurent Chiche
La Revue de Médecine Interne (2023)
Closed Access | Times Cited: 2
Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab
Yuma Motomura, Shin Urai, Yushi Hirota, et al.
Diabetology International (2023) Vol. 15, Iss. 1, pp. 130-134
Open Access | Times Cited: 2
Association of Survival With Immune-Related Adverse Events—Time to Consider the Duration of Treatment
Yu Fujiwara, Alessio Cortellini, Abdul Rafeh Naqash
JAMA Dermatology (2024) Vol. 160, Iss. 3, pp. 368-368
Closed Access
For the Long Haul: Management of Long-Term Survivors after Melanoma Systemic Therapy
Jordyn Silverstein, Neha Goyal, Katy K. Tsai
Current Oncology Reports (2024) Vol. 26, Iss. 7, pp. 804-817
Closed Access

Scroll to top